184 related articles for article (PubMed ID: 36593626)
21. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
Saygin D; Ghosh N; Reid P
J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
Tian CY; Ou YH; Chang SL; Lin CM
J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
[TBL] [Abstract][Full Text] [Related]
24. Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
Saad R; Ghaddar A; Zeenny RM
J Med Case Rep; 2024 Feb; 18(1):107. PubMed ID: 38383436
[TBL] [Abstract][Full Text] [Related]
25. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
26. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
27. Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis.
Nishikawa T; Kunimasa K; Ohta-Ogo K; Ikeda Y; Yasui T; Shioyama W; Oka T; Honma K; Hatakeyama K; Kumagai T; Fujita M
Intern Med; 2022 Jul; 61(14):2161-2165. PubMed ID: 35283377
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
[No Abstract] [Full Text] [Related]
29. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
[TBL] [Abstract][Full Text] [Related]
30. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
[TBL] [Abstract][Full Text] [Related]
31. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Chen JH; Lee KY; Hu CJ; Chung CC
Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
[TBL] [Abstract][Full Text] [Related]
32. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Safa H; Johnson DH; Trinh VA; Rodgers TE; Lin H; Suarez-Almazor ME; Fa'ak F; Saberian C; Yee C; Davies MA; Tummala S; Woodman K; Abdel-Wahab N; Diab A
J Immunother Cancer; 2019 Nov; 7(1):319. PubMed ID: 31753014
[TBL] [Abstract][Full Text] [Related]
34. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
[TBL] [Abstract][Full Text] [Related]
35. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
37. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
Puwanant A; Isfort M; Lacomis D; Živković SA
Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
[TBL] [Abstract][Full Text] [Related]
38. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
Front Immunol; 2021; 12():803410. PubMed ID: 34938300
[TBL] [Abstract][Full Text] [Related]
39. Cascade of immunologic adverse events related to pembrolizumab treatment.
Dhenin A; Samartzi V; Lejeune S; Seront E
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
[TBL] [Abstract][Full Text] [Related]
40. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
